6-(pyridine-5-ylmethoxy)-pyridine-3-ylamine | 287944-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(pyridine-5-ylmethoxy)-pyridine-3-ylamine
• 英文别名: 6-(pyridin-3-ylmethoxy)pyridin-3-amine
• CAS: 287944-14-3
• 化学式: C₁₁H₁₁N₃O
• 分子量: 201.228
• InChiKey: SPSLULZOGBODEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(pyridine-5-ylmethoxy)-pyridine-3-ylamine 在 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 6-chloro-5-methyl-N-[6-(pyridin-3-ylmethoxy)pyridin-3-yl]-2,3-dihydroindole-1-carboxamide
  参考文献：
  名称：

  1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists

  摘要：

  Bisarylmethoxyethers have been identified with nanomolar 5-HT2C affinity and selectivity over both 5-HT2A and 5-HT2B receptors. Compounds such as 1, 2, 8, 12, 14 and 18 have potent oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function and their therapeutic potential is currently under further investigation. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00365-6
• 作为产物：
  描述：

  3-吡啶甲醇 在 盐酸 、 sodium hydride 、 tin(ll) chloride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 6-(pyridine-5-ylmethoxy)-pyridine-3-ylamine
  参考文献：
  名称：

  1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists

  摘要：

  Bisarylmethoxyethers have been identified with nanomolar 5-HT2C affinity and selectivity over both 5-HT2A and 5-HT2B receptors. Compounds such as 1, 2, 8, 12, 14 and 18 have potent oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function and their therapeutic potential is currently under further investigation. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00365-6

文献信息

• NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT
  申请人：SEONG Churlmin

  公开号：US20090258876A1

  公开（公告）日：2009-10-15

  Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT 2c receptors, act selectively on the 5-HT 2c receptors, the derivatives rarely have adverse effects caused by other receptors. Because the derivatives effectively inhibit serotonin activity, they may be useful for treatment or prevention of obesity; urinary disorders such as urinary incontinence, premature ejaculation, erectile dysfunction, and prostatic hyperplasia; CNS disorders such as depression, anxiety, concern, panic disorder, epilepsy, obsessive-compulsive disorder, migraine, sleep disorder, withdrawal from drug abuse, Alzheimer's disease, and schizophrenia, associated with 5-HT 2c receptors.

  本公开涉及一种新的吲哚羧酸双吡啶羧酰胺衍生物，其制备方法，以及包含该衍生物作为活性成分的用于预防或治疗肥胖、泌尿系统疾病和中枢神经系统疾病的组合物。根据本发明的吲哚羧酸双吡啶羧酰胺衍生物具有高亲和力5-HT2c受体，对5-HT2c受体选择性作用，这些衍生物很少出现由其他受体引起的不良反应。由于这些衍生物有效抑制5-羟色胺活性，它们可能对治疗或预防肥胖；泌尿系统疾病，如尿失禁、早泄、勃起功能障碍和前列腺增生；以及与5-HT2c受体相关的中枢神经系统疾病，如抑郁症、焦虑症、关注症、恐慌症、癫痫、强迫症、偏头痛、睡眠障碍、戒毒、阿尔茨海默病和精神分裂症可能有用。
• Indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient
  申请人：Korea Research Institute of Chemical Technology

  公开号：US08324246B2

  公开（公告）日：2012-12-04

  Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT2c receptors, act selectively on the 5-HT2c receptors, the derivatives rarely have adverse effects caused by other receptors. Because the derivatives effectively inhibit serotonin activity, they may be useful for treatment or prevention of obesity; urinary disorders such as urinary incontinence, premature ejaculation, erectile dysfunction, and prostatic hyperplasia; CNS disorders such as depression, anxiety, concern, panic disorder, epilepsy, obsessive-compulsive disorder, migraine, sleep disorder, withdrawal from drug abuse, Alzheimer's disease, and schizophrenia, associated with 5-HT2c receptors.

  本发明公开了一种新的吲哚羧酸双吡啶基羧酰胺衍生物、其制备方法以及一种包含该衍生物作为活性成分的用于预防或治疗肥胖症、泌尿系统疾病和中枢神经系统疾病的组合物。由于本发明中的吲哚羧酸双吡啶基羧酰胺衍生物具有对5-HT2c受体的高亲和力，选择性地作用于5-HT2c受体，因此衍生物很少产生其他受体引起的不良反应。由于该衍生物能够有效抑制5-HT2c受体的血清素活性，因此可能对治疗或预防肥胖症、泌尿系统疾病（如尿失禁、早泄、勃起功能障碍和前列腺增生）以及与5-HT2c受体相关的中枢神经系统疾病（如抑郁症、焦虑症、担心症、惊恐障碍、癫痫、强迫症、偏头痛、睡眠障碍、药物滥用戒断、阿尔茨海默病和精神分裂症）有用。
• Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：EP2108649B1

  公开（公告）日：2013-04-24
• THERAPEUTIC QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1218355A1

  公开（公告）日：2002-07-03
• US7235559B1
  申请人：——

  公开号：US7235559B1

  公开（公告）日：2007-06-26